Quarterly report pursuant to Section 13 or 15(d)

Earnings Per Share

v3.22.2
Earnings Per Share
6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Earnings Per Share

Note 16 - Earnings Per Share

 

Basic earnings per share (“EPS”) excludes dilution and is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or otherwise result in the issuance of common stock that shared in the earnings of the entity. Diluted EPS also utilizes the treasury stock method which prescribes a theoretical buy back of shares from the theoretical proceeds of all options outstanding during the period, and the if-converted method for convertible debt.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (in thousands):

 

    June 30, 2022     June 30, 2021     June 30, 2022     June 30, 2021  
    For the three months ended     For the six months ended  
    June 30, 2022     June 30, 2021     June 30, 2022     June 30, 2021  
Net income - basic   $ 7,446     $ (1,395 )   $ 19,940     $ (338 )
Interest on unsecured convertible promissory note     200       -       432       -  
Net income - diluted   $ 7,646     $ (1,395 )   $ 20,372     $ (338 )
                                 
Weighted average shares outstanding - basic     15,576       15,154       15,531       14,860  
Diluted shares- Stock Options     2,635       -       2,389       -  
Diluted shares- Stock Warrants     261       -       244       -  
Unsecured convertible promissory note     800       -       800       -  
Weighted average shares outstanding - diluted     19,272       15,154       18,964       14,860  

 

The following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive effect (in thousands):

 

    For the three months ended     For the six months ended  
Anti-dilutive securities   June 30, 2022     June 30, 2021     June 30, 2022     June 30, 2021  
Common stock purchase warrants     455       4,378       455       4,378  
Stock Options     275       905       275       905  
Unsecured convertible promissory note     -       1,000       -       1,000  
Anti-dilutive securities     730       5,283       730       5,283